Foghorn Therapeutics Inc. 8-K

What Happened
Foghorn Therapeutics Inc. announced its financial results for the year ended December 31, 2025 via a press release issued March 11, 2026. The press release is furnished as Exhibit 99.1 to the Company’s Form 8‑K. In addition, Foghorn furnished an investor presentation dated March 2026 that it expects to use in meetings with investors; that presentation is included as Exhibit 99.2.

Key Details

• Press release announcing 2025 financial results issued March 11, 2026 (Exhibit 99.1).
• Investor presentation dated March 2026 intended for investor meetings (Exhibit 99.2).
• Both items were furnished with the Form 8‑K (see Exhibit list under Item 9.01).
• The 8‑K itself references the press release and presentation; detailed financial figures and operational updates appear in those exhibits rather than in the 8‑K text.

Why It Matters
This filing is the vehicle announcing Foghorn’s year‑end 2025 results and providing materials (press release and investor deck) where investors can find earnings, revenue, cash position, program updates and any management commentary. Retail investors should review Exhibits 99.1 and 99.2 for the specific financial metrics and guidance, since the Form 8‑K furnishes those documents rather than reciting the figures directly.